EAACI 2026

FLASH TALKS SESSION

Disease control and patient-reported outcomes from a Phase 4 open-label study in patients with hereditary angioedema switching to garadacimab from prior long-term prophylaxis

Presenting author: Dr Paul K. Keith

FLASH TALKS SESSION

Safety analysis of a Phase 4 study of patients with hereditary angioedema switching to garadacimab from prior prophylaxis

Presenting author: Dr Paul K. Keith

Click on a card to download the poster

Treatment that are not currently approved in Türkiye will be discussed in these Flash Talks, please refer to the regulatory guidance in your country.

EAACI, European Academy of Allergy and Clinical Immunology; HAE, hereditary angioedema; PRO, patient-reported outcome.